Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ersodetug · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Participants with a diagnosis of Tumor HI (insulin- or IGF-producing tumors) | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Ersodetug | DRUG | Ersodetug (9 mg/kg) + SOC |
Inclusion Criteria: * The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI, which must include an oncologist * Male or female participants of ≥18 years of age who provide written informed consent. * Clinical diagnosis of neuroendocrine tumor (NET)...
Ersodetug is an investigational small molecule being developed for Tumor Hyperinsulinism (Tumor HI), a condition of excess insulin secretion caused by tumors. It is currently in Phase 3 clinical development and has not been approved by the FDA.
Ersodetug is a small molecule, but its specific molecular target has not been disclosed. It is being studied for its ability to address Tumor Hyperinsulinism (Tumor HI), a condition characterized by excessive insulin production.
Ersodetug is being developed by Rezolute, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RZLT. The company is conducting a Phase 3 clinical trial for the drug in Tumor Hyperinsulinism.
Ersodetug is in Phase 3 clinical development. It is an investigational drug and has not received FDA approval. The drug has been granted Breakthrough Therapy and Orphan Drug designations by the FDA.
Ersodetug is being studied in a Phase 3 trial (NCT06881992) for Tumor Hyperinsulinism. The trial is recruiting 16 adult patients across the United States, France, Netherlands, Switzerland, and the United Kingdom. It is an open-label, uncontrolled study.
Ersodetug is the sole name provided for this investigational drug. No alternative names have been reported. It is a small molecule being developed by Rezolute, Inc. for Tumor Hyperinsulinism.